Gankyrin regulates cell signaling network

Tumor Biology

Volumn 37, Issue 5, 2016, Pages 5675-5682

  Wang, Xinxin ^a   Jiang, Bin ^a   Zhang, Yanjie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biomarker; Cancer; Cell signaling pathway; Drug target; Gankyrin

Indexed keywords

BETA CATENIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN GANKYRIN; PROTEIN KINASE B; PROTEIN ROCK; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; PROTEASOME; PSMD10 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR PROTEIN;

BILE DUCT CARCINOMA; BREAST CANCER; CANCER PROGNOSIS; CARCINOGENESIS; CHOLESTEATOMA; COLORECTAL CANCER; ENDOMETRIUM CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GERM CELL TUMOR; GLIOMA; HUMAN; INTRACELLULAR SIGNALING; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; OSTEOSARCOMA; OVARY CARCINOMA; PANCREAS CANCER; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; STOMACH CANCER; UTERINE CERVIX CARCINOMA; BIOLOGICAL MODEL; CELL TRANSFORMATION; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 84955568815     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4854-z     Document Type: Review

References (68)

1. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med. 2000;6:96–9.
2. Lozano G, Zambetti GP. Gankyrin: An intriguing name for a novel regulator of p53 and rb. Cancer Cell. 2005;8:3–4.
3. Dawson S, Higashitsuji H, Wilkinson AJ, Fujita J, Mayer RJ. Gankyrin: a new oncoprotein and regulator of prb and p53. Trends Cell Biol. 2006;16:229–33.
4. Li JN, Tsai MD. Novel insights into the ink4-cdk4/6-rb pathway: Counter action of gankyrin against ink4 proteins regulates the cdk4-mediated phosphorylation of rb. Biochemistry. 2002;41:3977–83.
5. Dawson S, Apcher S, Mee M, Higashitsuji H, Baker R, Uhle S, et al. Gankyrin is an ankyrin-repeat oncoprotein that interacts with cdk4 kinase and the s6 atpase of the 26 S proteasome. J Biol Chem. 2002;277:10893–902.
6. Mahajan A, Guo Y, Yuan CH, Weghorst CM, Tsai MD, Li JN. Dissection of protein-protein interaction and cdk4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and p16. J Mol Biol. 2007;373:990–1005.
7. Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, et al. The oncoprotein gankyrin binds to mdm2/hdm2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005;8:75–87.
8. Sun W, Ding J, Wu K, Ning BF, Wen W, Sun HY, et al. Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. Hepatol (Baltim, Md). 2011;54:1259–72.
9. Wang GL, Shi X, Haefliger S, Jin J, Major A, Iakova P, et al. Elimination of c/ebp(alpha) through the ubiquitin-proteasome system promotes the development of liver cancer in mice. J Clin Investig. 2010;120:2549–62.
10. Liu Y, Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Koike K, et al. Overexpression of gankyrin in mouse hepatocytes induces hemangioma by suppressing factor inhibiting hypoxia-inducible factor-1 (fih-1) and activating hypoxia-inducible factor-1. Biochem Biophys Res Commun. 2013;432:22–7.
11. Man JH, Liang B, Gu YX, Zhou T, Li AL, Li T, et al. Gankyrin plays an essential role in ras-induced tumorigenesis through regulation of the rhoa/rock pathway in mammalian cells. J Clin Investig. 2010;120:2829–41.
12. Wang WP, Yan XL, Li WM, Ni YF, Zhao JB, Lu Q, et al. Clinicopathologic features and prognostic implications of gankyrin protein expression in non-small cell lung cancer. Pathol Res Pract. 2015;211:939–47.
13. Jing H, Zhang G, Meng L, Meng Q, Mo H, Tai Y. Gradually elevated expression of gankyrin during human hepatocarcinogenesis and its clinicopathological significance. Sci Rep. 2014;4:5503.
14. Zhao X, Fu J, Xu A, Yu L, Zhu J, Dai R, et al. Gankyrin drives malignant transformation of chronic liver damage-mediated fibrosis via the rac1/jnk pathway. Cell Death Dis. 2015;6:e1751.
15. Liu Y, Zhang J, Qian W, Dong Y, Yang Y, Liu Z, et al. Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasis. PLoS One. 2014;9:e95043.
16. Kim YH, Kim JH, Choi YW, Lim SK, Yim H, Kang SY, et al. Gankyrin is frequently overexpressed in breast cancer and is associated with erbb2 expression. Exp Mol Pathol. 2013;94:360–5.
17. Zhen C, Chen L, Zhao Q, Liang B, Gu YX, Bai ZF, et al. Gankyrin promotes breast cancer cell metastasis by regulating rac1 activity. Oncogene. 2013;32:3452–60.
18. Gao L, Xie H, Dong L, Zou J, Fu J, Gao X, et al. Gankyrin is essential for hypoxia enhanced metastatic potential in breast cancer cells. Mol Med Rep. 2014;9:1032–6.
19. Tang S, Yang G, Meng Y, Du R, Li X, Fan R, et al. Overexpression of a novel gene gankyrin correlates with the malignant phenotype of colorectal cancer. Cancer Biol Ther. 2010;9:2.
20. Ortiz CM, Ito T, Tanaka E, Tsunoda S, Nagayama S, Sakai Y, et al. Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance. Int J Cancer. 2008;122:325–32.
21. Zheng TS, Hong XH, Wang JB, Pei TM, Liang YJ, Yin DL, et al. Gankyrin promotes tumor growth and metastasis through activation of il-6/stat3 signaling in human cholangiocarcinoma. Hepatol (Baltim, Md). 2014;59:935–46.
22. Zheng JY, Hu H, Du JJ, Li XH, Zhao QC. P28gank is a novel marker for prognosis and therapeutic target in gastric cancer. Mol Biol. 2014;48:84–90.
23. Yang Y, Zhang CL, Li L, Gao YS, Luo XM, Zhang YD, Liu WP, Fei Z. Up-regulated oncoprotein p28gank correlates with proliferation and poor prognosis of human glioma. World J Surg Oncol 2012;10.
24. Meng Y, He L, Guo X, Tang S, Zhao X, Du R, et al. Nie Y, liu J, Fan D: Gankyrin promotes the proliferation of human pancreatic cancer. Cancer Lett. 2010;297:9–17.
25. Li J, Knobloch TJ, Kresty LA, Zhang Z, Lang JC, Schuller DE, et al. Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Res. 2011;31:2683–92.
26. Wang GW, Rong JS, Zhou ZH, Duo JA. A novel gene p28gank confers multidrug resistance by modulating the expression of mdr-1, bcl-2, and bax in osteosarcoma cells. Mol Biol. 2010;44:898–906.
27. Zhang J, Yang Y, Zhang Z, He Y, Liu Z, Yu Y, et al. Gankyrin plays an essential role in estrogen-driven and gpr30-mediated endometrial carcinoma cell proliferation via the pten/pi3k/akt signaling pathway. Cancer Lett. 2013;339:279–87.
28. Kim KH, Lim HJ, Kim YJ, Kim SW, Kim YS, Tian C, et al. The oncoprotein, gankyrin, is up-regulated in middle ear cholesteatoma. Acta Otolaryngol. 2014;134:238–43.
29. Ando S, Matsuoka T, Kawai K, Sugita S, Joraku A, Kojima T, et al. Expression of the oncoprotein gankyrin and phosphorylated retinoblastoma protein in human testis and testicular germ cell tumor. Int J Urol. 2014;21:992–8.
30. Hwang J-A, Yang H-M, Hong D-P, Joo S-Y, Choi Y-L, Park J-H, et al. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. Oncotarget. 2014;5:9065–78.
31. Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H et al. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the pi3k/akt/hif-1alpha/cyclin d1 pathway. Oncogene 2015.
32. Qian YW, Chen Y, Yang W, Fu J, Cao J, Ren YB, et al. P28gank prevents degradation of oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis. Gastroenterology. 2012;142:1547–1558.e1514.
33. Jiang YJ, Iakova P, Jin JL, Sullivan E, Sharin V, Hong IH, et al. Farnesoid x receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatol (Baltim, Md). 2013;57:1098–106.
34. Luo T, Fu J, Xu A, Su B, Ren Y, Li N. et al. Psmd10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with atg7 and nuclear transactivation of atg7 expression. Autophagy 2015:0.
35. Li X, Zhang Y, Xiong C, Jin H, Jing B, Zhang Y, et al. Overexpression of a new gene p28gank confers multidrug resistance of gastric cancer cells. Cancer Investig. 2009;27:129–39.
36. Chen X, Zhang M, Liu LX. The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep 2009;22.
37. Downward J. Mechanisms and consequences of activation of protein kinase b/akt. Curr Opin Cell Biol. 1998;10:262–7.
38. Lim KH, Counter CM. Reduction in the requirement of oncogenic ras signaling to activation of pi3k/akt pathway during tumor maintenance. Cancer Cell. 2005;8:381–92.
39. Parsons R, Simpson L. Pten and cancer; in El-Deiry W (ed) Tumor suppressor genes. Humana Press. 2003;222:147–66.
40. Salmena L, Carracedo A, Pandolfi PP. Tenets of pten tumor suppression. Cell. 2008;133:403–14.
41. Etienne-Manneville S, Hall A. Rho gtpases in cell biology. Nature. 2002;420:629–35.
42. DerMardirossian C, Bokoch GM. Gdis: Central regulatory molecules in rho gtpase activation. Trends Cell Biol. 2005;15(7):356–63.
43. Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, et al. Regulation of pten by rho small gtpases. Nat Cell Biol. 2005;7:399–404.
44. Papakonstanti EA, Ridley AJ, Vanhaesebroeck B. The p110δ isoform of pi 3‐kinase negatively controls rhoa and pten. EMBO J. 2007;26:3050–61.
45. Sanchez T, Thangada S, Wu M-T, Kontos CD, Wu D, Wu H, et al. Pten as an effector in the signaling of antimigratory g protein-coupled receptor. Proc Natl Acad Sci U S A. 2005;102:4312–7.
46. Fu J, Chen Y, Cao J, Luo T, Qian YW, Yang W, et al. P28gank overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/akt/hypoxia-inducible factor-1alpha pathways. Hepatology. 2011;53:181–92.
47. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50.
48. Jamora C, Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat Cell Biol. 2002;4:E101–8.
49. Taipale J, Beachy PA. The hedgehog and wnt signalling pathways in cancer. Nature. 2001;411:349–54.
50. Dong LW, Yang GZ, Pan YF, Chen Y, Tan YX, Dai RY, et al. The oncoprotein p28(gank) establishes a positive feedback loop in beta-catenin signaling. Cell Res. 2011;21:1248–61.
51. Bai Z, Tai Y, Li W, Zhen C, Gu W, Jian Z, et al. Gankyrin activates il-8 to promote hepatic metastasis of colorectal cancer. Cancer Res. 2013;73:4548–58.
52. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D. et al. Lbh589 inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway. Mol Cancer 2013;12.
53. Santhanam U, Ray A, Sehgal PB. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1991;88:7605–9.
54. Zhu YM, Bradbury DA, Keith FJ, Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia. 1994;8:1982–8.
55. Church LD, Cook GP, McDermott MF. Primer: Inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42.
56. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. Nf-kappab functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.
57. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, et al. Deletion of nemo/ikkgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2007;11:119–32.
58. Karin M, Cao Y, Greten FR, Li ZW. Nf-kappab in cancer: From innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.
59. Karin M. The ikappab kinase - a bridge between inflammation and cancer. Cell Res. 2008;18:334–42.
60. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012;57:642–54.
61. Su B, Luo T, Zhu J, Fu J, Zhao X, Chen L, et al. Interleukin-1beta/iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent gankyrin activation during hepatocarcinogenesis. Hepatology. 2015;61:585–97.
62. Higashitsuji H, Higashitsuji H, Liu Y, Masuda T, Fujita T, Abdel-Aziz HI, et al. The oncoprotein gankyrin interacts with rela and suppresses nf-(kappa)b activity. Biochem Biophys Res Commun. 2007;363:879–84.
63. Chen Y, Li HH, Fu J, Wang XF, Ren YB, Dong LW, et al. Oncoprotein p28 gank binds to rela and retains nf-kappab in the cytoplasm through nuclear export. Cell Res. 2007;17:1020–9.
64. Ren YB, Luo T, Li J, Fu J, Wang Q, Cao GW, et al. P28(gank) associates with p300 to attenuate the acetylation of rela. Mol Carcinog. 2015;54:1626–35.
65. Chapman AM, McNaughton BR. Synthetic proteins potently and selectively bind the oncoprotein gankyrin, modulate its interaction with s6 atpase, and suppress gankyrin/mdm2-dependent ubiquitination of p53. ACS Chem Biol. 2015;10:1880–6.
66. Thakur PK, Hassan MI. Discovering a potent small molecule inhibitor for gankyrin using de novo drug design approach. Int J Comput Biol Drug Des. 2011;4:373–86.
67. Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, et al. Mir-605 represses psmd10/gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014;588:3491–500.
68. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paino T, et al. Restoration of microrna-214 expression reduces growth of myeloma cells through positive regulation of p53 and inhibition of DNA replication. Haematologica. 2013;98:640–8.